Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674308 · ClinicalTrials.gov registry record
Entyvio (Vedolizumab) Long Term Safety Study
A clinical trial, sponsored by Takeda.
- Completed
- Registry status
- 5,302
- Enrollment target
NCT02674308: Completed study, sponsored by Takeda.
NCT02674308 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 5,302 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02674308 has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 5,302 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).
Primary Outcome
Adverse events of special interest in this study includes serious and opportunistic infections, gastrointestinal infections, respiratory infections, other clinically significant infections: malignancies; infusion-related reactions and hypersensitivity, hepatic injury; psoriasis and other skin events, other SAEs and adverse reactions.
Interventions
- DRUG Vedolizumab
- OTHER Other Biologic Agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,302 participants |
| Start Date | 2015-03-24 |
| Est. Completion | 2021-07-30 |
What the finished NCT02674308 record still lists
NCT02674308 is an observational study that tracks outcomes without assigning an intervention. Its 5,302 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Vedolizumab is the first listed.
NCT02674308 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02674308 about?
NCT02674308 is a clinical study titled "Entyvio (Vedolizumab) Long Term Safety Study". The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).
What is the current status of trial NCT02674308?
This trial is currently completed. The enrollment target is 5,302 participants. The study started on 2015-03-24. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT02674308?
The interventions under investigation include: Vedolizumab (DRUG), Other Biologic Agents (OTHER).
Who is sponsoring clinical trial NCT02674308?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI